This article is more than 5 years old. Information may no longer be current.
Five recent highlights in atopic dermatitis research, development
Click Here to Manage Email Alerts
Recently published studies have compared guidelines for atopic dermatitis management and the possible contribution of human skin mast cells to the skin disorder.
Late-breaking research presented at the American Academy of Dermatology Annual Meeting and an FDA advisory committee meeting also focused on atopic dermatitis.
Guidelines for atopic dermatitis management differ with regard to therapies
Although the basic principles of atopic dermatitis management were similar in various guidelines, recommendations regarding adjunctive therapies differed, according to a recently published review. Read more.
Mast cells produce IL-22, may cause psoriasis, AD
Human skin mast cells are previously unrecognized interleukin-22 producers and express interleukin-17 that may contribute to inflammatory skin disorders, according to study results. Read more.
Novel boron-based ointment safe for treatment of atopic dermatitis in children
SAN FRANCISCO — AN2728 ointment 2%, a novel boron-based, small-molecule ointment, might be effective for the treatment of patients ages 2 years and older with mild-to-moderate atopic dermatitis, according to research presented during a late-breaking research session at the American Academy of Dermatology Annual Meeting. Read more.
VIDEO: Researcher looks at relationship between atopic dermatitis, obesity and cardiovascular disease
SAN FRANCISCO — In this video, Jonathan I. Silverberg, MD, PhD, MPH, discusses studies examining cardiovascular risk in atopic dermatitis that he reviewed at the American Academy of Dermatology meeting.
Jonathan I. Silverberg
“Both children and adults with atopic dermatitis are at higher risk for obesity and cardiovascular disease,” Silverberg, an assistant professor of dermatology, medical social sciences and preventive medicine at Northwestern University Feinberg School of Medicine, told Healio.com/Dermatology. Watch video.
FDA advisory committee agrees on need for pediatric studies on atopic dermatitis
An FDA advisory committee agreed there is an unmet medical need for systemic products, drugs and biologics, along with additional clinical studies, for the treatment of children with atopic dermatitis who do not respond adequately to topical therapy.
Lawrence Eichenfield
Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego, spoke during the open public hearing section of the meeting, as a representative for Roche-Genentech. Read more.